Clinical Trial Update: Bevacizumab and Retinal Vascular Occlusions [Phase 3]

View source ↗

Summary

A Phase 3 trial of bevacizumab for macular edema and retinal vascular occlusion has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinal Vascular Occlusion

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Asociación para Evitar la Ceguera en México | Conditions: Edema Macular, Vascular Occlusion | Phase 3 | Status: WITHDRAWN